On October 24, 2022 Theriva Biologics (NYSE American: TOVX), ("Theriva" or the "Company"), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, reported a presentation of previously released data from a Phase 1 investigator-sponsored study evaluating VCN-01 in combination with durvalumab for patients with recurrent/ metastatic squamous cell carcinoma of the head and neck (R/M HNSCC) (Press release, Theriva Biologics, OCT 24, 2022, View Source [SID1234622309]). Data will be featured in an oral presentation at the 14th International Oncolytic Virotherapy (IVOC) Conference, being held from in Karuizawa, Japan from October 23-26.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details on the presentation can be found below.
Title: VCN-01 changes tumor stroma when administered systemically in combination with Durvalumab (MEDI4736) in subjects with recurrent/ metastatic squamous cell carcinoma of the head and neck (R/M HNSCC): Biological data of a Phase I Study
Abstract: 0136
Presenter: Frank Tufaro, Ph.D., Chief Operating Officer of Theriva Biologics
Presentation Date and Time: Tuesday, October 25, 2022 at 11:20 a.m. JST/Monday, October 24, 2022 at 10:00 p.m. ET
Location: Karuizawa Prince Hotel West
A copy of the presentation will be accessible under the ‘Events’ section of the Theriva Biologics website.